financetom
Business
financetom
/
Business
/
Drop in funding costs: MSMEs struggling while top-rated draw money cheap
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Drop in funding costs: MSMEs struggling while top-rated draw money cheap
Dec 1, 2020 5:46 AM

AAA rated NBFCs were able to access money at 5-5.5 percent for the last couple of months, but with liquidity being ample the cost of funding for second, third tier NBFCs has come off quite a bit.

“Cost of funding has gone down by 40 bps in first half of FY21,” said Sanjay Chamria, VC & MD of Magma Fincorp in an interview to CNBC-TV18.

According to him, micro, small and medium enterprises (MSMEs) are struggling for funds while top rated companies are drawing money cheap.

Meanwhile, R Sridhar, Executive VC & CEO of Indostar Capital Finance expects further decline in cost of funds.

According to Sridhar, average cost of funds will come down by 25-30 bps by March 2021.

On business front, Indostar is looking at portfolio acquisitions and inorganic moves. The company has decided to wind down corporate business subsequent to IL&FS (crisis).

“There is no impact of corporate lending business exit as retail lending business is going to go up,” added Sridhar.

For entire discussion, watch video

(Edited by : Abhishek Jha)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
GSK Reports Positive Results From Interim Analysis of Test of Potential Blood Cancer Treatment -- Shares Up Pre-Bell
GSK Reports Positive Results From Interim Analysis of Test of Potential Blood Cancer Treatment -- Shares Up Pre-Bell
Mar 7, 2024
06:51 AM EST, 03/07/2024 (MT Newswires) -- GSK (GSK) said Thursday that it had received positive results from an interim analysis of a late-stage study of its potential multiple myeloma treatment Blenrep in combination with pomalidomide plus dexamethasone compared with bortezomib plus dexamethasone. The company said the trial, involving 302 patients, met its primary endpoint of progression-free survival at a...
Nvidia Insider Sold Shares Worth $170,020,366, According to a Recent SEC Filing
Nvidia Insider Sold Shares Worth $170,020,366, According to a Recent SEC Filing
Mar 7, 2024
06:48 AM EST, 03/07/2024 (MT Newswires) -- Tench Coxe, Director, on March 05, 2024, sold 200,000 shares in Nvidia ( NVDA ) for $170,020,366. Following the Form 4 filing with the SEC, Coxe has control over a total of 3,787,612 shares of the company, with 5,228 shares held directly and 3,782,384 shares controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1045810/000122520824003814/xslF345X03/doc4.xml ...
BRIEF-Jyong Biotech Files For Us IPO
BRIEF-Jyong Biotech Files For Us IPO
Mar 7, 2024
March 7 (Reuters) - * JYONG BIOTECH LTD. FILES FOR US IPO * JYONG BIOTECH LTD.: JOSEPH STONE CAPITAL, LLC WILL BE UNDERWRITER FOR IPO Source text for Eikon: ...
Bilibili's Q4 Adjusted Loss Narrows, Revenue Increases
Bilibili's Q4 Adjusted Loss Narrows, Revenue Increases
Mar 7, 2024
06:47 AM EST, 03/07/2024 (MT Newswires) -- Bilibili ( BILI ) posted a Q4 adjusted loss Thursday of 1.34 Chinese renminbi ($0.19) per diluted American depositary share, compared with a loss of 3.31 renminbi a year earlier. Analysts polled by Capital IQ expected an adjusted loss of 1.57 renminbi. Revenue for the quarter ended Dec. 31 was 6.35 billion renminbi,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved